Umitrelimorgene autodencel is under clinical development by Immunomic Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Umitrelimorgene autodencel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Umitrelimorgene autodencel overview

Umitrelimorgene autodencel (ITI-1000) is under development for the treatment of glioblastoma multiforme (GBM). It is administered intradermally. The vaccine candidate autologous dendritic cells loaded with mRNA encoding the hLAMP gene fused to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and administered with adjuvants GM-CSF and Tetanus/diphtheria (Td) toxoid. It is developed based on Lysosomal-Associated Membrane Protein (LAMP-vax) technology. It was under development for the recurrent malignant glioma or recurrent medulloblastoma.

Immunomic Therapeutics overview

Immunomic Therapeutics (ITI), a subsidiary of HLB Co Ltd, is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology-based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune responses including antibody production, cytokine release, and crITIcal immunological memory. Its oncology pipeline products at various stages of development include ITI-1000, ITI-1001, ITI-3000, and ITI-8000. The company’s products also include ASP-4070 and ASP-0892 for treating allergies. The company also develops LAMP-vax technology vaccines that encode the expression of a fusion protein comprising the therapeutic antigen and the LAMP targeting protein. The company partners with academic centers and biotechnology companies to study the use of the UNITE platform in treating glioblastoma and acute myeloid leukemia. ITI is headquartered in Rockville, Maryland, the US.

For a complete picture of Umitrelimorgene autodencel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.